Key result
Heart transplantation eligibility expands toward personalized risk assessment for complex stage D heart failure.
Why the study?
Current heart transplantation practice increasingly extends beyond traditional eligibility criteria into patients with complex clinical and social profiles, requiring personalized risk assessment, multidisciplinary decision-making, and ethical oversight.
This review summarizes the shift in heart transplantation from strict eligibility contraindications toward personalized multidisciplinary risk assessment for patients with complex clinical and social comorbidities, alongside emerging strategies to expand the donor pool.
Answers are grounded in this paper and cite their sources.
Supports individualized risk assessment for expanded transplant candidacy; leaves open optimal ethical allocation frameworks.
Heart transplantation (HTx) remains the definitive therapy for selected patients with stage D heart failure; however, current practice increasingly extends beyond traditional eligibility criteria. Progress in mechanical circulatory support, donor management, immunosuppressive therapies, and perioperative care has facilitated transplantation in patients with complex clinical profiles, including advanced age, obesity, chronic infections, prior malignancies, substance use disorders, and socioeconomic vulnerabilities. This review traces the evolution from strict contraindications to personalized risk assessment supported by multidisciplinary transplant teams and ethical oversight. The discussion encompasses clinical decision-making between HTx and left ventricular assist devices, incorporating INTERMACS profiles, end-organ function, frailty, psychosocial evaluation, donor availability, and waiting times. Emerging strategies to broaden the donor pool, such as donation after circulatory death, normothermic regional perfusion, and ex-vivo heart perfusion, are examined with respect to safety and clinical outcomes. Particular attention is paid to combined heart-kidney transplantation, management of recipients with chronic viral infections, and collaboration with cardio-oncology for patients with histories of cancer. Finally, the review addresses ethical considerations related to equity, organ allocation, and shared decision-making, as well as future directions including precision transplant medicine, artificial intelligence-based risk modeling, and evolving ethical frameworks aimed at enhancing outcomes amid persistent organ scarcity.
No takes yet. Share an insight, caveat, or question.
Bohdan et al. (2026) conducted a review in Stage D heart failure with complex clinical and social profiles. Heart transplantation vs. Left ventricular assist devices was evaluated. Heart transplantation eligibility has expanded from strict contraindications to personalized risk assessment for complex stage D heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: